F-D-C Reports, Windhover Information and Boston Healthcare Associates proudly present:
How To Maximize Your Reimbursement Value Through Pharmacoeconomic And Outcomes Research
Adapting to the Changing Dossier Environment: Creating Pharmacoeconomic and Health Outcomes Data That Will Impact Coverage and Formulary Decisions
WEBINAR: Thursday, June 26, 2008 - 12:00 pm ET / 9 am PT / 90 minutes - This Webinar is now over. To order a CD of the event please contact Heej Ko at Tel: +1 (203) 838-4401 x 133.
FEATURING:
- Gina Ford, Executive Director - Boston Healthcare
- Phil Cyr, Director - Boston Healthcare
- Click here for speaker bios
COST:
WEBINAR: Thursday, June 26, 2008 - 12:00 pm ET / 9 am PT / 90 minutes - This Webinar is now over. To order a CD of the event please contact Heej Ko at Tel: +1 (203) 838-4401 x 133.
- Webinar: $399
- Live webinar plus complete audio recording: $499
- Audio recording only: $499
ABOUT THE WEBINAR:
A recent survey of health plan pharmacy directors indicated that they felt that more than half of the economic models submitted as part of the AMCP were inadequate. In addition, WellPoint's Outcomes-based FormularySM Guidelines, which were heavily influenced by international health technology assessment organizations such as NICE and the Australian Technology Assessment Agencies, have drastically increased health economic and outcomes evidentiary requirements for new drug submissions.
Recently, US health care payers have increased their efforts to incorporate pharmacoeconomic and health outcomes data into their coverage and formulary decisions. Changes in the AMCP dossier now require budget-impact, quality-of-life, and cost-of-illness information for your new products. Furthermore,
you now have to emphasize the need for greater transparency of health economic and outcomes data submitted, especially cost-effectiveness models.
But what are the health economics and outcomes research changes to the AMCP dossier? And do you know all the key evidentiary requirements of WellPoint's Outcomes-based FormularySM Guidelines? Find out exactly what you need to know about these changes BEFORE it's time to submit your next drug for approval.
So join us, in the convenience of your own office, for a thought-provoking analysis. Grab your team (or several teams), a conference room at your office, a phone and a computer with Web access (that last one's optional). No travel required.
Walk away with valuable answers to the following questions:
- How do you conduct the right pharmacoeconomic and health outcomes analyses for your new products?
- What are the evidentiary requirements of the AMCP and WellPoint Dossiers related to health economics and outcomes research?
- What are some "real-world" examples of the impact pharmacoeconomic information will have on payers' decisions?
- How are U.S. pharmacy and medical directors use pharmacoeconomic and outcomes research in their decision-making process?
- How do you maximize your reimbursement value through pharmacoeconomic and outcomes research?
- How are U.S. payers will use pharmacoeconomic and outcomes research in the coming years?
- Which pharmacoeconomic studies are most commonly used for payer coverage and formulary decisions, and what you should know about them?
- How are private health plans are using pharmacoeconomic information?
- What role will pharmacoeconomics and outcomes research will play in the public payer sector?
... and much more!
More webinar information HERE!
For more information on Windhover products and conferences, visit us at
http://www.windhover.com, or send an email to [email protected].
Windhover Information
10 Hoyt St., Norwalk, CT 06851
* Tel: +1 (203) 838-4401 x 113
* Fax: +1 (203) 838-3214
.jpg)
.jpg)
